August 11, 2023 – Myriad Genetics and Intermountain Precision Genomics, part of the Intermountain Health system, will begin providing oncology test results that allow access to the ComboMATCH trials. ComboMATCH is a coordinated platform of clinical oncology trials sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. Led by the NCI and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), ComboMATCH aims to help identify and show the efficacy of new anti-cancer drug combinations for patients with locally advanced or metastatic solid tumor cancers.
ComboMATCH includes a Patient Registration Trial led by ECOG-ACRIN, along with several treatment trials designed and led by the Alliance for Clinical Trials in Oncology, Children’s Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network. These groups are members of the NCI’s National Clinical Trials Network (NCTN).
In ComboMATCH, researchers in the NCTN groups will seek to improve cancer patient outcomes using new combinations of biomarker targeted therapies beyond the current standard of care. To be selected for the trial, combinations must show evidence they may be more effective than single therapy in treating cancer. Patients with locally advanced or metastatic cancer with eligible genetic testing completed through Intermountain or Myriad may have the opportunity to enroll in the ComboMATCH Patient Registration Trial (EAY191) to receive these types of combination therapies to target genetic mutations in their tumor cells and/or their germline.
In 2021, Myriad and Intermountain announced a collaboration on a comprehensive offering of germline and somatic tumor testing, known as Precise™ Oncology Solutions, leveraging the strengths of Myriad’s MyRisk® germline test and Intermountain’s somatic Theramap assay. Both the Myriad and Intermountain tests are now able to be used to identify patients that may be eligible for enrollment in a treatment study under ComboMATCH.